上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002252 上海莱士

已收盘 07-03 15:00:00

{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":4.61,"timestamp":1783062195000,"preClose":4.53,"halted":0,"volume":61828763,"delay":0,"changeRate":0.0177,"floatShares":6588000000,"shares":6593000000,"eps":0.2013,"marketStatus":"已收盘","change":0.08,"latestTime":"07-03 15:00:00","open":4.55,"high":4.65,"low":4.54,"amount":284000000,"amplitude":0.0243,"askPrice":4.62,"askSize":2229,"bidPrice":4.61,"bidSize":3101,"shortable":0,"etf":0,"ttmEps":0.2013,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":4.53,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":4.98,"lowLimit":4.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":0.92,"roa":"--","peRate":22.901143,"roe":"0.97%","epsLYR":0.24,"committee":-0.357587,"marketValue":30392000000,"turnoverRate":0.0094,"status":0,"floatMarketCap":30371000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2649561643","title":"股市必读：上海莱士（002252）7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649561643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649561643?lang=zh_cn&edition=full","pubTime":"2026-07-06 02:33","pubTimestamp":1783276390,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，上海莱士报收于4.61元，上涨1.77%，换手率0.94%，成交量61.83万手，成交额2.84亿元。欧美等海外国家血液制品终端价格受其医疗体系与医保支付规则、产品供需格局、临床使用场景等影响。前期国内市场体量庞大，公司经营重心主要深耕国内市场。当日关注点交易信息汇总：7月3日主力资金净流出838.66万元，游资资金净流入1063.44万元，散户资金净流出224.78万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600000877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","002252","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654915","title":"上海莱士：公司将积极推进海外市场法规注册与长期贸易机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648654915?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:21","pubTimestamp":1783066875,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月03日在投资者关系平台上答复投资者关心的问题。欧美等海外国家血液制品终端价格受其医疗体系与医保支付规则、产品供需格局、临床使用场景等影响。前期国内市场体量庞大，公司经营重心主要深耕国内市场。公司后续将积极推进海外市场法规注册与长期贸易机会，推动海外业务稳健发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300029262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0188","002252","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648505285","title":"上海莱士(002252)6月18日股东户数11.65万户，较上期增加1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648505285","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648505285?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:37","pubTimestamp":1782985024,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年6月18日公司股东户数为11.65万户，较5月29日增加1479.0户，增幅为1.29%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至6月18日，生物制品行业平均股东户数为3.57万户。从股价来看，2026年5月29日至2026年6月18日，上海莱士区间跌幅为12.43%，在此期间股东户数增加1479.0户，增幅为1.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200029519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0239","BK0188","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648057507","title":"上海莱士：以终端动销驱动取代传统销售模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2648057507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648057507?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:34","pubTimestamp":1782963254,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月01日在投资者关系平台上答复投资者关心的问题。目前公司以终端动销驱动取代传统销售模式，通过拉动销、降库存、促回款、保发货的闭环管理，同时深耕医院、零售、第三终端市场等方式，实现经营质量的提升。血液制品刚需属性强、存货库龄整体健康，存货减值风险可控。后续随着渠道库存逐步消化、终端动销回暖，财务指标也将持续改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200015018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002252","BK0046","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648859576","title":"上海莱士：受政策与市场竞争影响产品价格下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2648859576","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648859576?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:34","pubTimestamp":1782963253,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2025年营收与归母净利润双双下滑，且2026年一季度营收同比大降24.75%，归母净利润暴跌44.21%。受国家增值税相关政策、行业政策、市场竞争、渠道库存调整等因素影响，血液制品相关产品价格均有所下滑。公司已全面推进营销改革，依托精益管理降本控费，同时布局创新药与新增市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200015017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0239","BK0188","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648750785","title":"上海莱士：截至2026年6月18日，公司股东总户数为116,541户","url":"https://stock-news.laohu8.com/highlight/detail?id=2648750785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648750785?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:34","pubTimestamp":1782963253,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止6月20号，公司的股东人数是多少？谢谢上海莱士回复：感谢您的关注！截至2026年6月18日，公司股东总户数为116,541户。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200015016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0196","BK0046","002252","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648576864","title":"上海莱士：全面推进营销改革、精益降本、创新药研发等举措改善经营基本面","url":"https://stock-news.laohu8.com/highlight/detail?id=2648576864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648576864?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:34","pubTimestamp":1782963250,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月01日在投资者关系平台上答复投资者关心的问题。目前行业处于周期调整，景气反转受库存消化、供需平衡、政策变化等多重因素影响。公司正在全面推进营销改革、精益降本、创新药研发等举措改善经营基本面。公司控股股东和管理层高度重视当前股价走势，股价受行业周期、板块情绪等多重因素影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200015012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0028","159992","002252","BK0196","BK1574","BK0239","BK0046","BK0188","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648575042","title":"上海莱士：管理层薪酬与公司业绩、个人绩效相挂钩","url":"https://stock-news.laohu8.com/highlight/detail?id=2648575042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648575042?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:34","pubTimestamp":1782963250,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月01日在投资者关系平台上答复投资者关心的问题。近几年公司持续科学优化高管薪酬与绩效考核体系，于本年度制定并披露了《董事、高级管理人员薪酬管理制度》，管理层薪酬与公司业绩、个人绩效相挂钩，与公司长远利益相结合，共享成果、共担责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200015011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0188","BK0028","BK0196","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340375","title":"上海莱士：公司将持续深入研究相关政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340375?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:30","pubTimestamp":1782703819,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月28日在投资者关系平台上答复投资者关心的问题。我们理解您提到的上海出台支持生物医药外资医药简便通关是指近期上海发布的《关于支持生物医药外资企业高能级项目落地的若干措施》中提到的政策。公司将持续深入研究相关政策，结合自身进口业务布局、货物入境口岸统筹规划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900012453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0188","BK0239","BK0046","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646358312","title":"6月26日上海莱士创60日新低，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646358312?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:50","pubTimestamp":1782463807,"startTime":"0","endTime":"0","summary":"根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.1亿元，最新净值0.3547，较上一交易日上涨0.91%，近一年下跌6.58%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0188","BK0239","BK0046","399441","BK0196","BK0028","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646180720","title":"股市必读：6月25日上海莱士现367.11万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2646180720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646180720?lang=zh_cn&edition=full","pubTime":"2026-06-26 01:23","pubTimestamp":1782408188,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，上海莱士报收于4.46元，下跌1.33%，换手率0.9%，成交量59.03万手，成交额2.63亿元。当日关注点交易信息汇总：6月25日主力资金净流出2964.79万元；  交易信息汇总：当日发生367.11万元大宗交易；  交易信息汇总：散户资金净流入2938.07万元，与主力资金流向呈明显背离。大宗交易6月25日上海莱士发生367.11万元大宗交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600000809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0046","BK0239","BK0196","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646803854","title":"上海莱士：公司通过重塑营销体系、调整市场策略等方式启动营销组织的整合与变革","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646803854?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:52","pubTimestamp":1782391938,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月24日在投资者关系平台上答复投资者关心的问题。公司通过重塑营销体系、调整市场策略等方式启动营销组织的整合与变革，目前改革已初见成效。控股股东入主后，重塑公司治理体系，统一集团标准化管理，确立“拓浆+脱浆”中长期核心战略，同步落地股份回购、注销等资本运作举措。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500041749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","BK0239","BK0188","BK0028","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646803861","title":"上海莱士：目前控股股东及其一致行动人合计表决权比例已达30.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803861","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646803861?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:52","pubTimestamp":1782391937,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月24日在投资者关系平台上答复投资者关心的问题。目前控股股东及其一致行动人合计表决权比例已达30.10%，该比例是公司回购注销股份后被动抬升，已依规披露免于要约收购的提示性公告。若满足法定豁免情形可免于发出要约；如不符合豁免条件，则需依法履行要约收购程序。公司管理层及控股股东均坚定看好企业长期发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500041747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0046","BK0196","BK0028","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646803865","title":"上海莱士：已实施大额增持并支持股份回购及注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646803865?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:52","pubTimestamp":1782391936,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月24日在投资者关系平台上答复投资者关心的问题。上市公司股价，受到行业周期、政策变化、市场情绪等多重因素影响。海盈康成为控股股东后，已实施大额增持，并支持公司完成股份回购及注销；同步落地精益管理、组织优化、创新药研发布局等改革工作。若后续筹划资产重组，公司将严格按照监管规则及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500041745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0239","BK0028","BK0196","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646250188","title":"上海莱士：线上低价主要为下游经销商行为","url":"https://stock-news.laohu8.com/highlight/detail?id=2646250188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646250188?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:36","pubTimestamp":1782358575,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月24日在投资者关系平台上答复投资者关心的问题。公司为基立福人血白蛋白在中国大陆地区的独家经销商，线上低价主要为下游经销商行为，并非公司定价；且2026年5月新版《药品管理法实施条例》已明确规定血液制品不得通过网络销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500018342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0196","BK0239","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646252178","title":"上海莱士：GDS经营稳健，具备正向价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2646252178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646252178?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:30","pubTimestamp":1782358231,"startTime":"0","endTime":"0","summary":"公司将GDS视为联营企业按权益法核算，隐含商誉列示在长期股权投资的账面价值中。每年年末，公司会聘请专业的评估和审计机构对长期股权投资进行减值测试。同时，基立福还承诺，只要其继续直接或间接控制GDS，其应会促使GDS在本次交易交割后的每个会计年度向其股东宣派金额不少于GDS在该财政年度净利润50%的股息。目前，GDS经营稳健，对公司有稳定的投资收益以及分红回报，具备正向价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500017870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0239","BK0188","BK0028","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645017635","title":"海尔入主上海莱士两年浮亏66亿：周云杰等持股高管财富缩水多少","url":"https://stock-news.laohu8.com/highlight/detail?id=2645017635","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645017635?lang=zh_cn&edition=full","pubTime":"2026-06-22 09:39","pubTimestamp":1782092340,"startTime":"0","endTime":"0","summary":"两年前的2024年6月18日，海尔集团通过下属公司海盈康(青岛)医疗科技有限公司（下称“海盈康”）完成对上海莱士（002252）的战略入股交割，完成以125亿元对上海莱士20%股权收购。6月17日，上海莱士确定2025年分红方案，每10股派现0.33元（含税），合计派现约2.17亿元。同日，上海莱士收盘价4.69元/股，较收购9.4元/股的成本价已“腰斩”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223777296621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","01169","BK0188","BK0046","BK0196","002252","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645096737","title":"每周股票复盘：上海莱士（002252）现溢价12.53%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2645096737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645096737?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:36","pubTimestamp":1781984173,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，上海莱士报收于4.65元，较上周的5.01元下跌7.19%。本周，上海莱士6月15日盘中最高价报5.05元。来自公司公告汇总：上海莱士2025年年度权益分派方案为每10股派发现金股利0.33元（含税），股权登记日为2026年6月23日。交易信息汇总6月16日上海莱士现1笔溢价12.53%的大宗交易，合计成交377.3万元。6月15日上海莱士发生2219万元大宗交易。本次实际现金分红总额为216,773,795.21元，折算每10股现金红利为0.328810元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0239","BK0028","BK0196","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085249","title":"上海莱士：2025年公司完成了大额回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085249","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644085249?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:52","pubTimestamp":1781787142,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问：2024年海尔以每股9.4元价格入主至今市值蒸发一半，请问贵公司及控股股东是否有回购股票计划？上海莱士回复：感谢您的关注！2025年公司完成了大额回购并于近期完成了前述部分回购股份的注销，控股股东也于2025年实施了多次增持，充分彰显对公司的长期信心。公司将持续聚焦主业提升盈利，依托规范市值管理体系维护股东权益，若后续推出相关安排，将依规及时公告。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800040572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","BK0239","002252","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644779447","title":"上海莱士：南岳生物浆站、产能、产品文号具备稀缺性","url":"https://stock-news.laohu8.com/highlight/detail?id=2644779447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644779447?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:36","pubTimestamp":1781753778,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问：25年开启的血制品产能危机，公司如何评价之前的高溢价对南岳生物的收购？上海莱士回复：感谢您的关注！血制品行业生产牌照与浆站资源稀缺，南岳生物作为湖南独家血制品生产企业，其浆站、产能、产品文号具备稀缺性，属于长期战略布局。公司将进一步推进内部整合优化，全面落地提质增效，为公司长远稳健发展筑牢核心支撑。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800017311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0239","BK0188","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783285357162,"stockEarnings":[{"period":"1week","weight":0.0696},{"period":"1month","weight":-0.114},{"period":"3month","weight":-0.1953},{"period":"6month","weight":-0.2659},{"period":"1year","weight":-0.3193},{"period":"ytd","weight":-0.2659}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"116541人(较上一季度增加1.29%)","perCapita":"56529股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":"　　上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}